Table 6.
Analysis of DNA Synthesis in LS-174 Tumor Xenografts Following Bimodal Treatment with 212Pb Radioimmunotherapy and Carboplatin
| |
|
Timepoint (hours) |
|||||
|---|---|---|---|---|---|---|---|
| RIT | Chemotherapy | 0 | 6 | 24 | 48 | 72 | 96 |
| None | None | 17.8a | |||||
| None | Carboplatin | 17.1 | 16.5 | 14.4 | 13.5 | 8.4 | |
| Trastuzumab | None | ND | 9.8 | 0.7 | 0.5 | 0.9 | |
| Trastuzumab | Carboplatin | 24.6 | 3.3 | 0.5 | 0.9 | 0.2 | |
| HuIgG | None | ND | 7.6 | 1.7 | 6.0 | 7.6 | |
| HuIgG | Carboplatin | 15.4 | 4.0 | 2.2 | 2.1 | 5.5 | |
a
The values presented are the percentage of DNA synthesis determined by flow cytometric analysis for 5-bromo-2′-deoxyuridine incorporation.